Exploring the immunotherapeutic potential of Vγ9Vδ2-T cells in cancer using bispecific antibodies
Bispecific T cell engagers (bsTCEs) are engineered antibodies designed to simultaneously bind a tumor-associated antigen (TAA) and, most commonly, the CD3 complex on T cells. By bridging tumor and effector cells, bsTCEs promote the formation of an immunological synapse that triggers potent cytotoxic responses, bypassin...